Konruns(SH:603590) Xin Lang Cai Jing·2026-01-05 02:33Core Viewpoint - Kangchen Pharmaceutical's stock price has shown a slight increase of 2.01% this year, but has experienced a decline of 9.81% over the past 20 days and 22.69% over the past 60 days, indicating volatility in its stock performance [2]. Group 1: Stock Performance - As of January 5, Kangchen Pharmaceutical's stock price reached 40.55 CNY per share, with a trading volume of 30.14 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 6.448 billion CNY [1]. - The stock has increased by 2.01% year-to-date, with a minor increase of 0.22% over the last five trading days, while it has seen significant declines of 9.81% over the last 20 days and 22.69% over the last 60 days [2]. Group 2: Company Overview - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, is located in Beijing and focuses on innovative drug research and development, integrating R&D, production, and sales [2]. - The company's main business revenue is derived from Suling (70.77%), Salmon Calcitonin (29.15%), and other sources (0.09%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the sub-sector of other biological products, and is associated with concepts such as monkeypox, biopharmaceuticals, innovative drugs, venture capital, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical reported a revenue of 692 million CNY, reflecting a year-on-year growth of 7.10%, and a net profit attributable to shareholders of 128 million CNY, which is a 13.19% increase compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 437 million CNY in dividends, with 175 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangchen Pharmaceutical reached 10,700, an increase of 7.18% from the previous period, with an average of 14,806 circulating shares per shareholder, a decrease of 6.12% [2]. - Notable new institutional shareholders include Qianhai Kaiyuan HuGangShen Advantage Selection Mixed A (holding 1.7445 million shares), Qianhai Kaiyuan China Scarce Asset Mixed A (holding 1.6075 million shares), and others, while several previous major shareholders have exited the top ten list [3].